Crizanlizumab is a monoclonal antibody developed by Novartis targeted towards P-selectin. It was announced by the company as an effective drug to prevent vaso-occlusive crisis in patients with Sickle cell anemia. The result of the Phase II SUSTAIN clinical trial was published in December 2016.
- "Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease". New England Journal Medicine. Retrieved 5 December 2016.
- "Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies" (122(24)). 2013: 3892–3898.